Skylark initiates trial of gene therapy for hearing loss
Skylark Bio has dosed the first patient in the SONIX Phase I/II clinical trial evaluating SKY-GJB2, its investigational inner-ear-targeted gene therapy for GJB2-mediated hearing loss.
“Dosing the first patient in SONIX brings us one step closer to a future where children born with genetic hearing loss have new treatment options that could meaningfully change the trajectory of their lives. SONIX is designed to generate preliminary data by year-end 2026 with additional readouts anticipated in 2027. The recent approval of a targeted inner-ear AAV-delivered therapy provides important validation for the field and further reinforces our confidence in this approach,” said Dr Jodi Cook, Chief Executive Officer of Skylark Bio.
GJB2‑related hearing loss is the most common genetic cause of nonsyndromic deafness and one of the most prevalent and tractable monogenic forms of hearing disorders. Genetic changes in GJB2 disrupt the function of connexin 26, a protein essential to the gap-junction network of the inner ear and maintenance of normal hearing function.
SKY-GJB2 is designed as a potential first-in-class therapy to address the underlying cause of GJB2-related hearing loss by precisely delivering a functional copy of GJB2 to supporting cells in the cochlea that naturally express connexin 26, with the goal of restoring the gap-junction network essential for hearing.
“Launching the SONIX trial marks an exciting milestone for children and families affected by GJB2-related hearing loss,” said Dr Daniel Lee, Ansin Foundation Chair in Otolaryngology at Massachusetts Eye and Ear and Scientific Advisor to Skylark Bio. “Although current interventions provide meaningful benefits, they do not address the underlying genetic cause. We look forward to evaluating SKY-GJB2 and its potential to support more natural hearing and spoken-language development.”
